hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 00:02:52 - browse：85225

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Body of missing toddler recovered in Delaware River days after flood: Police

WSS

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Kim Kardashian sparks debate on benefits of full

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

entertainment

hotspot

explore

Duchenne breakthrough therapy leaves behind pioneering families

Body of missing toddler recovered in Delaware River days after flood: Police

Moonlake's readout produced a cash windfall. Risks remain

Timeline: Special counsel's investigation into Trump's handling of classified documents

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Cancer drug shortages should be causing more outrage

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Novo acquires Inversago for up to $1 billion

hotspot

TB outbreak tied to bone grafts underscores testing shortcomings

Genentech weighs delaying cancer therapy after drug pricing law

Russian special forces kill a gunman who broke into a private house near Moscow

The history of OxyContin, told through Purdue Pharma documents

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Caitlin Bernard's story shows physicians can't shy from advocacy

knowledge

focus

entertainment

entertainment